Relevant bibliographies by topics / Anticholinergika

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Anticholinergika'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anticholinergika.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anticholinergika"

1

Müller, Th. "Wirkmechanismus der Anticholinergika." Aktuelle Neurologie 25, S 4 (December 1998): S252—S253. http://dx.doi.org/10.1055/s-2007-1017736.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Michel, M. C., M. M. Barendrecht, and M. Oelke. "Anticholinergika bei überaktiver Blase." Der Urologe 45, no. 7 (July 2006): 826–29. http://dx.doi.org/10.1007/s00120-006-1075-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Goepel, M., and D. Schultz-Lampel. "Anticholinergika bei OAB-Syndrom." Der Urologe 50, no. 7 (June 18, 2011): 802–5. http://dx.doi.org/10.1007/s00120-011-2602-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Madersbacher, H. "Orale Anticholinergika bei überaktiver Blase." Der Urologe 45, no. 7 (July 2006): 830–34. http://dx.doi.org/10.1007/s00120-006-1096-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hochgesand, D., and N. Pfeiffer. "Systemische Anticholinergika: selten kontraindiziert bei Glaukompatienten." Aktuelle Urologie 32, no. 05 (September 18, 2001): 252–55. http://dx.doi.org/10.1055/s-2001-17266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schumacher, Beate. "Anticholinergika: Kommt es zu geistigem Abbau?" CME 17, no. 10 (October 2020): 28–29. http://dx.doi.org/10.1007/s11298-020-8063-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Heppner, Hans Jürgen. "Erhöhtes Pneumonie-Risiko bei Älteren durch Anticholinergika." Pneumo News 8, no. 4 (August 2016): 28–29. http://dx.doi.org/10.1007/s15033-016-0439-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Riem, Ludger. "Selektive Anticholinergika: stark wirksam an der Blase." Uro-News 16, no. 1 (January 2012): 50. http://dx.doi.org/10.1007/s00092-012-0032-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tietze, Ulrike. "Überaktive Blase im Alter: Vorsicht mit Anticholinergika!" gynäkologie + geburtshilfe 18, no. 3 (May 2013): 58. http://dx.doi.org/10.1007/s15013-013-0117-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Meißner, Thomas. "Überaktive Blase: Botulinumtoxin bei unzureichender Anticholinergika-Wirkung." gynäkologie + geburtshilfe 20, S7 (September 2015): 54. http://dx.doi.org/10.1007/s15013-015-0770-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anticholinergika"

1

Bierwisch, Michael. "Synthese und Charakterisierung neuer potentieller M3- selektiver Anticholinergika mit Diphenylessigsäurestruktur zur Therapie der Harninkontinenz." [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=967140315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bierwisch, Michael. "Synthese und Charakterisierung neuer potentieller M 3 -selektiver Anticholinergika mit Diphenylessigsäurestruktur zur Therapie der Harninkontinenz." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2003. http://dx.doi.org/10.18452/14835.

Full text
Abstract:
Zusammenfassung: Im Hinblick auf eine medikamentöse Behandlung der Harninkontinenz ist die Entwicklung neuartiger, selektiv und damit nebenwirkungsreduzierter, am Muscarin-M3-Rezeptor wirkender Therapeutika ein wichtiges Ziel der Pharmaforschung. An verschiedenen stickstoffhaltigen und stickstofffreien Esterderivaten der 2,2-Diphenylessigsäure (Alkyl-, Cycloalkyl, Aminoalkyl- und Piperidinylester) wurden über die Generierung von Enolatstrukturen mit Hilfe metallorganischer Verbindungen systematisch elektrophile Additionsreaktionen mit einer breiten Palette von Alkyl- und Acylhalogeniden, Acylcyaniden sowie Carbonylverbindungen durchgeführt. Durch Variation von Lösungsmittel, verwendeter Base sowie Änderungen in der Struktur von Elektrophil und Substrat konnten neue Erkenntnisse bezüglich der Reaktivität und Regioselektivität dieser sterisch gehinderten Esterenolate gewonnen werden. Die experimentellen Ergebnisse konnten durch Röntgenkristallstrukturanalysen sowie semiempirische Berechnungen bestätigt werden.
abstract: The development of new M3-selective muscarinic antagonists for use in therapy of urinary incontinence is an important goal of drug research. This thesis describes investigations of synthesis and reactivity of ester enolates of diphenylacetic acid derivatives, which are intermediates in the synthesis of anticholinergic agents. A series of aliphatic, cycloaliphatic , aminoalkyl and piperidinyl esters were prepared using lithium alkyles and / or grignard compounds followed by addition of various electrophiles such as acid chlorides, aldehydes, ketones or alkylating reagents. Studies involving variations of solvents and bases and modifications of substrate and electrophile structure have lead to new information about reactivity of these sterically hindered ester enolates. The experimental results were confirmed by x-ray analysis and semiempirical calculations.
APA, Harvard, Vancouver, ISO, and other styles
3

Riegelmann, Jörn [Verfasser], Roland [Akademischer Betreuer] Nau, and Martin [Akademischer Betreuer] Oppermann. "Beeinflussung der Phagozytose von Pneumokokken durch Mikrogliazellen mit Anticholinergika / Jörn Riegelmann. Gutachter: Roland Nau ; Martin Oppermann. Betreuer: Roland Nau." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2013. http://d-nb.info/1046446460/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fontaine, Olivier. "Anticholinergie et memoires." Lille 2, 1994. http://www.theses.fr/1994LIL2M057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bosman, Ingrid Jolanda. "Transdermal delivery of anticholinergic bronchodilators methodological and clinical aspects /." [S.l. : [Groningen] : s.n.] ; [University Library Groningen] [Host], 1996. http://irs.ub.rug.nl/ppn/148592155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kemper, Rachel F. "Anticholinergic Medications Used by Older Adults with Memory Problems." University of Toledo Health Science Campus / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=mco1115054101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dare, Reese. "Prophylactic Anticholinergic Medications to Prevent Drug-Induced Extrapyramidal Symptoms: A Systematic Review." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623294.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
Neuroleptic medications are commonly administered in the emergency department but are known to induce extrapyramidal symptoms (EPS) in some patients; typically dystonia and akathisia. This systematic review will examine if adjunctive medications are efficacious when given in conjunction with neuroleptic medications to prevent these extrapyramidal symptoms. The Central, DARE, LILACS, PubMed, CINAHL, and OVID databases were searched for relevant articles between January 2014 and February 2016. Inclusion criteria required the article to be a randomized controlled trial; administer an anticholinergic medication given concurrently or just prior to treatment with medications with known extrapyramidal side effects; and be published in English. The initial search strategy yielded 1222 prospective articles of which 1208 were excluded by title and/or abstract. Fourteen articles were retrieved in full text and independently reviewed by each author. Seven 7 RCTs representing 645 patients were determined to be appropriate for analysis. Meta‐analysis of 5 studies found a significant effect (OR 0.4 with 95% CI 0.23‐0.71) for utilizing anticholinergic adjunct medications in the prevention of EPS for 60 minutes after administration. No reduction was found (OR 1.14 with 95% CI 0.01‐164) in EPS after 60 minutes in meta‐analysis of 2 studies with opposing results. Adjunctive anticholinergic medication was effective in reducing symptoms of dystonia (OR 0.13 with 95% CI 0.04‐0.43) but not in reducing symptoms of akathisia (OR 0.74 with 95% CI 0.27‐1.98). This systematic review found that anticholinergic adjuvant anticholinergic treatment reduced EPS induced by antipsychotic medications during 60 minutes after administration, with the greatest reduction in dystonic symptoms.
APA, Harvard, Vancouver, ISO, and other styles
8

Gjerden, Pål. "The use of anticholinergic antiparkinson agents in Norway : Epidemiology, toxicology and clinical implications." Doctoral thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for laboratoriemedisin, barne- og kvinnesykdommer, 2010. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-11667.

Full text
Abstract:
This thesis is based on two fundamental questions: Which patients are currently using anticholinergic antiparkinson drugs? Does it matter which anticholinergic antiparkinson drug they are using? These questions were further investigated, using a variety of methods, as follows: Are anticholinergic antiparkinson agents predominantly used to treat Parkinson’s disease or antipsychotic induced extrapyramidal side-effects (EPS)? Is there a high risk of abuse of anticholinergic antiparkinson agents? Can alleged differences in receptor binding profiles of typical first- (FGA) and atypical second (SGA) -generation antipsychotic agents predict concomitant use of anticholinergic agents? Can long-term co-prescription of anticholinergic antiparkinson agents shed some light on the efficacy of antipsychotic agents? Does the literature indicate differences in toxicity and fatality rates of anticholinergic antiparkinson agents? Does an autopsy material indicate differences between anticholinergic agents regarding toxicity and fatality risk? Are warnings in a medical journal against the use of the most toxic anticholinergic agent enough to reduce its use? Can patients stop using anticholinergic agents without further remedies? The thesis has the following conclusions: The overwhelming majority of anticholinergic users were patients concomitantly using antipsychotic agents, presumably for the alleviation of antipsychotic induced EPS. The use of anticholinergics was not particularly skewed and we could not find any other indication of abuse, indicating that concomitant use of anticholinergics can be a proxy for the liability of specific antipsychotic agents to cause EPS. For patients using only one antipsychotic agent, the concurrent use of anticholinergics varied between 0.4% and 26.0%, but largely independently of the distinction between typical and atypical antipsychotics. High D2-receptor antagonism and a high 5-HT2A/D 2- receptor-affinity ratio coincided with the use of anticholinergics. Clozapine and zuclopentixol demonstrated the highest level of prescription persistence in a three-year period. The high prevalence of concomitant use of anticholinergics and zuclopentixol may indicate that the latter was considered efficacious enough to outweigh its probable side-effects. Haloperidol was associated with a mortality three times that of any other antipsychotic agent in the study. Orphenadrine is by far the most toxic anticholinergic antiparkinson agent with a high mortality risk. Warnings in a medical journal against the use of a toxic drug can have an impact on prescription patterns. At least one-third of the patients using anticholinergic antiparkinson agents do not need them.
APA, Harvard, Vancouver, ISO, and other styles
9

Chyan, Vivian, Megan Shell, and Lisa Goldstone. "Evidence-Based Use of Prophylactic Anticholinergic Medication in Combination with Antipsychotic Pharmacotherapy in an Acute Inpatient Psychiatric Setting." The University of Arizona, 2015. http://hdl.handle.net/10150/614026.

Full text
Abstract:
Class of 2015 Abstract
Objectives: The study aimed to increase EPS risk factor assessment when prescribers order prophylactic anticholinergics with antipsychotics. An evidence-based pharmacist checklist card was developed to aid in this decision making process. Methods: A retrospective chart review of patients admitted to the acute inpatient psychiatry units at an academic medical center was conducted to determine baseline prophylactic anticholinergic prescribing habits over a two-month period. Charts were included if the patient was at least 18 years old and ordered at least one scheduled antipsychotic during the admission. An educational intervention session introduced the pharmacist checklist card and shared baseline findings. Post-intervention data was collected during a two-month period following the intervention. The percentage of prophylactic anticholinergic orders based upon pharmacist checklist card parameters pre and post-intervention was analyzed using chi-square test. Results: There was a significant decrease in the total percentage of orders for prophylactic anticholinergics from 72.7% in the pre-intervention period to 50.8% in the post-intervention period (p<0.001). Significant changes in the percentage of orders for prophylactic anticholinergics were also found for patients at no-to-low risk for EPS (56.4% versus 31.8%, p=0.014) and at low-to-moderate risk for EPS (79.6% versus 50.8%, p=0.003). There were no significant changes observed in the percentage of orders for prophylactic anticholinergics for patients at moderate-to-high risk for EPS. A lower percentage of patients prescribed a prophylactic anticholinergic experienced adverse effects in the post versus the pre-intervention period (52.31% versus 75.27%, p=0.003). Conclusions: Significant differences were found between pre and post-intervention anticholinergic medication prescribing habits. This suggests that increased patient risk factor assessment in the form of a pharmacist checklist card is effective in decreasing orders for prophylactic anticholinergic medications not clinically indicated and reducing the incidence of adverse effects.
APA, Harvard, Vancouver, ISO, and other styles
10

Flores-Pamo, Adrian Ernesto, Elinor Pisano, and Nilton Yhuri Carreazo. "Anticholinergic toxicity in a one-year-old male following ingestion of Lupinus mutabilis seeds: case report." Associação Paulista de Medicina - APM, 2017. http://hdl.handle.net/10757/622420.

Full text
Abstract:
CONTEXT: The seeds from Lupinus mutabilis Sweet, also called “chocho”, are an important part of the diet in several countries in South America. Prior to consumption, processing is required to remove toxic alkaloids. These alkaloids are known to have pharmacological properties as antiarrhythmics, antimuscarinics and hypoglycemics. CASE REPORT: We report a case in which a one-year-old male initially presented with altered mental status and respiratory distress and subsequently developed symptoms of anticholinergic toxicity, after ingesting a large amount of chocho seeds. CONCLUSION: In spite of going through a difficult clinical condition, the subject evolved favorably through receiving supportive treatment. The seeds from Lupinus mutabilis provide nutritional benefits when consumed, but people need to know their risks when these seeds are consumed without proper preparation.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anticholinergika"

1

Fanapour, Philip, Peggy White, and Brenda G. Fahy. Anticholinergic Overdose. Edited by Matthew D. McEvoy and Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0095.

Full text
Abstract:
Anticholinergic toxidrome can be a side effect of medications or herbal therapies or can result from intentional or inadvertent overdose of prescribed medications or abused substances. The diagnosis of anticholinergic toxicity involves symptomatology, including tachycardia, hyperthermia, central nervous system dysfunction including delirium, and urinary retention. The diagnosis can be challenging, as it is based on clinical symptoms with presentation mimicking other etiologies. Early diagnosis and intervention with treatment are key with the specific identification of the agent involved and other confounding substances. Discontinuation of the agent(s) involved as early as possible and providing supportive care are early interventions, with additional therapeutic options determined by the severity of the toxicity and the agent(s) involved.
APA, Harvard, Vancouver, ISO, and other styles
2

1946-, Barnes P. J., and Buist A. Sonia 1940-, eds. The role of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. Macclesfield: Gardiner-Caldwell Communications, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Parker, Philip M. The 2007-2012 World Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

The 2006-2011 World Outlook for Antispasmodic and Anticholinergic H2 Blocking Agents. Icon Group International, Inc., 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Parker, Philip M. The 2007-2012 World Outlook for Antispasmodic and Anticholinergic H2 Blocking Agents. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Parker, Philip M. The 2007-2012 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in India. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Parker, Philip M. The 2007-2012 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in Japan. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Parker, Philip M. The 2007-2012 Outlook for Antispasmodic and Anticholinergic H2 Blocking Agents in Japan. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Parker, Philip M. The 2007-2012 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in Greater China. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Parker, Philip M. The 2007-2012 Outlook for Antispasmodic and Anticholinergic H2 Blocking Agents in Greater China. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Anticholinergika"

1

Saller, Reinhard. "Anticholinergika." In Metoclopramid als Standardantiemetikum in der Behandlung zytostatikainduzierten Erbrechens, 46. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77782-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kummer, F. "Anticholinergika." In Pharmakotherapie bronchopulmonaler Erkrankungen, 43–51. Vienna: Springer Vienna, 2000. http://dx.doi.org/10.1007/978-3-7091-6761-8_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Przuntek, H., and G. Ulm. "Anticholinergika." In Neuro-Psychopharmaka, 15–27. Vienna: Springer Vienna, 1992. http://dx.doi.org/10.1007/978-3-7091-3330-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wink, Michael. "Anticholinergika." In Handbuch Psychoaktive Substanzen, 701–13. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-642-55125-3_53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wink, Michael. "Anticholinergika." In Handbuch Psychoaktive Substanzen, 1–19. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-642-55214-4_53-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peter, Helga, and Thomas Penzel. "Anticholinergika." In Springer Reference Medizin, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_316-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ammermann, C., H. Grimm, and C. Pöpperl. "Anticholinergika — grundsätzliche oder gezielte Anwendung?" In Vorbereitung des Patienten zu Anästhesie und Operation, 373–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-71474-0_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Noll, F. "Indikation zur Frühbehandlung der Reflexblase mit Anticholinergika." In Rehabilitation beginnt am Unfallort, 218–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77231-3_47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nolte, D. "Autonomes Nervensystem und Atemwege: Angriffspunkte für Anticholinergika." In Fokus — Atemwegserkrankungen heute, 17–21. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72768-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schultze-Werninghaus, G. "Stellenwert der Anticholinergika bei allergischem Asthma im Erwachsenenalter." In Das cholinerge System der Atemwege, 61–74. Vienna: Springer Vienna, 1992. http://dx.doi.org/10.1007/978-3-7091-9208-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anticholinergika"

1

Villalba-Moreno, A., E. Alfaro-Lara, S. Sanchez-Hidalgo, MD Nieto-Martin, A. Garcia-Avello, C. Perez-Guerrero, and B. Santos-Ramos. "OHP-027 Anticholinergic burden web tool calculator." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morillo Mora, AB, and V. Gonzalez Rosa. "5PSQ-222 Anticholinergic risk in the elderly." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.341.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Boix Montañés, ADP, I. Torre Lloveras, and O. Carrascosa Piquer. "4CPS-202 Anticholinergical risk in chronic complex patients." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Molostova, Tatiana, Alexander Chuchalin, Yuri Kalinin, Sofia Skachilova, and Oksana Proskurina. "Comparative activity of ilmetropium iodide and other anticholinergic drugs." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa5260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Byrne, Patrick, and Jennifer Hoblyn. "H55 Anticholinergic drug burden and cognitive function in huntington’s disease." In EHDN 2018 Plenary Meeting, Vienna, Austria, Programme and Abstracts. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/jnnp-2018-ehdn.233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tristancho-Pérez, A., S. Belda Rustarazo, MD López-Malo, MD Santos-Rubio, M. Galván-Banqueri, and S. Sánchez Fidalgo. "5PSQ-157 Impact of anticholinergic burden, quantified by anticholinergic risk scales, on cognitive and functional status and falls in patients with multimorbidity: a preliminary study." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yuan, Wei, Shan Nie, Haoyan Wang, Qiufen Xu, and Nan Jia. "Inhaled anticholinergics affect the heart rate recovery in stable COPD patients." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa781.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Oro Fernandez, M., CM Valencia Soto, JI Gutierrez Revilla, F. Perez Hernandez, and A. Tejerina. "5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Velasco Costa, J., JM Peñalver Gonzalez, and M. Martinez De Guzman. "5PSQ-182 Anticholinergic burden in patients admitted to a psychiatric hospital." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Plaza Diaz, A., J. Ruiz Ramos, A. Juanes Borrego, M. Blazquez Andion, L. Lopez Vinardell, and MA Mangues Bafalluy. "4CPS-002 Anticholinergic burden in constipated patient admitted to an emergency department." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.103.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anticholinergika"

1

Wilson, Barry E. Improving Blood Monitoring of Enzymes as Biomarkers of Risk From Anticholinergic Pesticides and Chemical Warfare Agents. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada416001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wilson, Barry W. Improving Blood Monitoring of Enzymes as Biomarkers of Risk Form Anticholinergic Pesticides and Chemical Warfare Agents. Fort Belvoir, VA: Defense Technical Information Center, October 2003. http://dx.doi.org/10.21236/ada419695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Carger, Elizabeth A., and Erwin J. Tan. Concurrent Anticholinergic and Acetylcholinesterase Inhibitor Drug Use Among Older Adults with Dementia: Commonly Done; Never Advised. AARP Public Policy Institute, June 2021. http://dx.doi.org/10.26419/ppi.00137.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Update on anticholinergic therapy for OAB. BJUI Knowledge, December 2016. http://dx.doi.org/10.18591/bjuik.0050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anticholinergika' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography